Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1997 Apr;65(4):1321–1326. doi: 10.1128/iai.65.4.1321-1326.1997

A protective role of platelet-activating factor in murine candidiasis.

S Y Im 1, J H Choi 1, H M Ko 1, S J Han 1, S B Chun 1, H K Lee 1, T Y Ha 1
PMCID: PMC175135  PMID: 9119469

Abstract

Platelet-activating factor (PAF) is a potent phospholipid-derived modulator of immunological and inflammatory processes. In this study, the role of exogenous and endogenous PAF in resistance to infection with Candida albicans was investigated. Administration of PAF following a lethal challenge of C. albicans significantly protected mice from death and reduced the number of organisms in the kidneys. Neutralization of endogenous PAF with the PAF antagonist BN50739 shortened the mean survival time and increased the number of C. albicans cells per kidney. Shortly after infection of mice (30 min), significant levels of PAF were detected in the serum. PAF-induced protection appears to be mediated through the actions of tumor necrosis factor alpha (TNF-alpha), since pretreatment with anti-TNF-alpha before each injection of PAF abrogated the majority of PAF-induced enhanced resistance. Administration of PAF in vivo elevated serum TNF-alpha levels and TNF-alpha mRNA expression in the kidney. Production of TNF-alpha was markedly diminished by pretreatment with the PAF antagonist BN50739 prior to infection with C. albicans. We conclude that PAF, which is produced during infection with C. albicans, plays an important role in determining the level of resistance to this infectious microorganism. This effect of PAF appears to be mediated, at least in part, through the induction of TNF-alpha.

Full Text

The Full Text of this article is available as a PDF (232.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aderka D., Holtmann H., Toker L., Hahn T., Wallach D. Tumor necrosis factor induction by Sendai virus. J Immunol. 1986 Apr 15;136(8):2938–2942. [PubMed] [Google Scholar]
  2. Allendoerfer R., Magee D. M., Smith J. G., Bonewald L., Graybill J. R. Induction of tumor necrosis factor-alpha in murine Candida albicans infection. J Infect Dis. 1993 May;167(5):1168–1172. doi: 10.1093/infdis/167.5.1168. [DOI] [PubMed] [Google Scholar]
  3. Ashman R. B., Papadimitriou J. M. Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol Rev. 1995 Dec;59(4):646–672. doi: 10.1128/mr.59.4.646-672.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ashman R. B. The influence of graft size on the induction of immunity versus tolerance to H-Y in H-2k strains of mice. Immunogenetics. 1985;22(6):585–591. doi: 10.1007/BF00430306. [DOI] [PubMed] [Google Scholar]
  5. Barral-Netto M., Badaró R., Barral A., Almeida R. P., Santos S. B., Badaró F., Pedral-Sampaio D., Carvalho E. M., Falcoff E., Falcoff R. Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J Infect Dis. 1991 Apr;163(4):853–857. doi: 10.1093/infdis/163.4.853. [DOI] [PubMed] [Google Scholar]
  6. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  7. Bodey G. P. Candidiasis in cancer patients. Am J Med. 1984 Oct 30;77(4D):13–19. [PubMed] [Google Scholar]
  8. Braquet P., Touqui L., Shen T. Y., Vargaftig B. B. Perspectives in platelet-activating factor research. Pharmacol Rev. 1987 Jun;39(2):97–145. [PubMed] [Google Scholar]
  9. Brummer E., Morrison C. J., Stevens D. A. Recombinant and natural gamma-interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect Immun. 1985 Sep;49(3):724–730. doi: 10.1128/iai.49.3.724-730.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bussolino F., Breviario F., Tetta C., Aglietta M., Mantovani A., Dejana E. Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. J Clin Invest. 1986 Jun;77(6):2027–2033. doi: 10.1172/JCI112532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Camussi G., Aglietta M., Coda R., Bussolino F., Piacibello W., Tetta C. Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology. 1981 Feb;42(2):191–199. [PMC free article] [PubMed] [Google Scholar]
  12. Camussi G., Bussolino F., Salvidio G., Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med. 1987 Nov 1;166(5):1390–1404. doi: 10.1084/jem.166.5.1390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Casals-Stenzel J. Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock. Eur J Pharmacol. 1987 Mar 17;135(2):117–122. doi: 10.1016/0014-2999(87)90602-9. [DOI] [PubMed] [Google Scholar]
  14. Chignard M., Le Couedic J. P., Tence M., Vargaftig B. B., Benveniste J. The role of platelet-activating factor in platelet aggregation. Nature. 1979 Jun 28;279(5716):799–800. doi: 10.1038/279799a0. [DOI] [PubMed] [Google Scholar]
  15. Choi I. H., Ha T. Y., Lee D. G., Park J. S., Lee J. H., Park Y. M., Lee H. K. Occurrence of disseminated intravascular coagulation (DIC) in active systemic anaphylaxis: role of platelet-activating factor. Clin Exp Immunol. 1995 Jun;100(3):390–394. doi: 10.1111/j.1365-2249.1995.tb03711.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  17. Djeu J. Y., Blanchard D. K., Richards A. L., Friedman H. Tumor necrosis factor induction by Candida albicans from human natural killer cells and monocytes. J Immunol. 1988 Dec 1;141(11):4047–4052. [PubMed] [Google Scholar]
  18. Dofferhoff A. S., Esselink M. T., de Vries-Hospers H. G., van Zanten A., Bom V. J., Weits J., Vellenga E. The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes. J Antimicrob Chemother. 1993 Mar;31(3):373–384. doi: 10.1093/jac/31.3.373. [DOI] [PubMed] [Google Scholar]
  19. Dubois C., Bissonnette E., Rola-Pleszczynski M. Platelet-activating factor (PAF) enhances tumor necrosis factor production by alveolar macrophages. Prevention by PAF receptor antagonists and lipoxygenase inhibitors. J Immunol. 1989 Aug 1;143(3):964–970. [PubMed] [Google Scholar]
  20. Floch A., Bousseau A., Hetier E., Floc'h F., Bost P. E., Cavero I. RP 55778, a PAF receptor antagonist, prevents and reverses LPS-induced hemoconcentration and TNF release. J Lipid Mediat. 1989 Nov-Dec;1(6):349–360. [PubMed] [Google Scholar]
  21. Garner R. E., Rubanowice K., Sawyer R. T., Hudson J. A. Secretion of TNF-alpha by alveolar macrophages in response to Candida albicans mannan. J Leukoc Biol. 1994 Feb;55(2):161–168. doi: 10.1002/jlb.55.2.161. [DOI] [PubMed] [Google Scholar]
  22. Gonzalez-Crussi F., Hsueh W. Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. Am J Pathol. 1983 Jul;112(1):127–135. [PMC free article] [PubMed] [Google Scholar]
  23. Hsueh W., Sun X., Rioja L. N., Gonzalez-Crussi F. The role of the complement system in shock and tissue injury induced by tumour necrosis factor and endotoxin. Immunology. 1990 Jul;70(3):309–314. [PMC free article] [PubMed] [Google Scholar]
  24. Huang L., Tan X., Crawford S. E., Hsueh W. Platelet-activating factor and endotoxin induce tumour necrosis factor gene expression in rat intestine and liver. Immunology. 1994 Sep;83(1):65–69. [PMC free article] [PubMed] [Google Scholar]
  25. Im S. Y., Ko H. M., Kim J. W., Lee H. K., Ha T. Y., Lee H. B., Oh S. J., Bai S., Chung K. C., Lee Y. B. Augmentation of tumor metastasis by platelet-activating factor. Cancer Res. 1996 Jun 1;56(11):2662–2665. [PubMed] [Google Scholar]
  26. Jeremias J., Kalo-Klein A., Witkin S. S. Individual differences in tumour necrosis factor and interleukin-1 production induced by viable and heat-killed Candida albicans. J Med Vet Mycol. 1991;29(3):157–163. doi: 10.1080/02681219180000261. [DOI] [PubMed] [Google Scholar]
  27. Jouault T., Lepage G., Bernigaud A., Trinel P. A., Fradin C., Wieruszeski J. M., Strecker G., Poulain D. Beta-1,2-linked oligomannosides from Candida albicans act as signals for tumor necrosis factor alpha production. Infect Immun. 1995 Jun;63(6):2378–2381. doi: 10.1128/iai.63.6.2378-2381.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kagaya K., Fukazawa Y. Murine defense mechanism against Candida albicans infection. II. Opsonization, phagocytosis, and intracellular killing of C. albicans. Microbiol Immunol. 1981;25(8):807–818. doi: 10.1111/j.1348-0421.1981.tb00084.x. [DOI] [PubMed] [Google Scholar]
  29. Kagaya K., Shinoda T., Fukazawa Y. Murine defense mechanism against Candida albicans infection. I. Collaboration of cell-mediated and humoral immunities in protection against systemic C. albicans infection. Microbiol Immunol. 1981;25(7):647–654. doi: 10.1111/j.1348-0421.1981.tb00068.x. [DOI] [PubMed] [Google Scholar]
  30. Klein R. S., Harris C. A., Small C. B., Moll B., Lesser M., Friedland G. H. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. 1984 Aug 9;311(6):354–358. doi: 10.1056/NEJM198408093110602. [DOI] [PubMed] [Google Scholar]
  31. Kullberg B. J., van 't Wout J. W., Hoogstraten C., van Furth R. Recombinant interferon-gamma enhances resistance to acute disseminated Candida albicans infection in mice. J Infect Dis. 1993 Aug;168(2):436–443. doi: 10.1093/infdis/168.2.436. [DOI] [PubMed] [Google Scholar]
  32. Kurlander R. J., Hoffman M., Kratz S. S., Gates J. Comparison of the effects of IL-1 alpha and TNF-alpha on phagocyte accumulation and murine antibacterial immunity. Cell Immunol. 1989 Oct 1;123(1):9–22. doi: 10.1016/0008-8749(89)90264-5. [DOI] [PubMed] [Google Scholar]
  33. Louie A., Baltch A. L., Smith R. P., Franke M. A., Ritz W. J., Singh J. K., Gordon M. A. Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis. Infect Immun. 1994 Jul;62(7):2761–2772. doi: 10.1128/iai.62.7.2761-2772.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Marks J. D., Marks C. B., Luce J. M., Montgomery A. B., Turner J., Metz C. A., Murray J. F. Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis. 1990 Jan;141(1):94–97. doi: 10.1164/ajrccm/141.1.94. [DOI] [PubMed] [Google Scholar]
  35. Mencia-Huerta J. M., Benveniste J. Platelet-activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes. Eur J Immunol. 1979 May;9(5):409–415. doi: 10.1002/eji.1830090512. [DOI] [PubMed] [Google Scholar]
  36. Montrucchio G., Lupia E., Battaglia E., Passerini G., Bussolino F., Emanuelli G., Camussi G. Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med. 1994 Jul 1;180(1):377–382. doi: 10.1084/jem.180.1.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Morrison C. J., Brummer E., Isenberg R. A., Stevens D. A. Activation of murine polymorphonuclear neutrophils for fungicidal activity by recombinant gamma interferon. J Leukoc Biol. 1987 May;41(5):434–440. doi: 10.1002/jlb.41.5.434. [DOI] [PubMed] [Google Scholar]
  38. Nakane A., Minagawa T., Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun. 1988 Oct;56(10):2563–2569. doi: 10.1128/iai.56.10.2563-2569.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Nawroth P. P., Stern D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986 Mar 1;163(3):740–745. doi: 10.1084/jem.163.3.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Ogata M., Matsumoto T., Koga K., Takenaka I., Kamochi M., Sata T., Yoshida S., Shigematsu A. An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan. Infect Immun. 1993 Feb;61(2):699–704. doi: 10.1128/iai.61.2.699-704.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Opal S. M., Cross A. S., Kelly N. M., Sadoff J. C., Bodmer M. W., Palardy J. E., Victor G. H. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis. 1990 Jun;161(6):1148–1152. doi: 10.1093/infdis/161.6.1148. [DOI] [PubMed] [Google Scholar]
  42. Pecyk R. A., Fraser-Smith E. B., Matthews T. R. Efficacy of interleukin-1 beta against systemic Candida albicans infections in normal and immunosuppressed mice. Infect Immun. 1989 Oct;57(10):3257–3258. doi: 10.1128/iai.57.10.3257-3258.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Pisa P., Gennene M., Söder O., Ottenhoff T., Hansson M., Kiessling R. Serum tumor necrosis factor levels and disease dissemination in leprosy and leishmaniasis. J Infect Dis. 1990 May;161(5):988–991. doi: 10.1093/infdis/161.5.988. [DOI] [PubMed] [Google Scholar]
  44. Puccetti P., Mencacci A., Cenci E., Spaccapelo R., Mosci P., Enssle K. H., Romani L., Bistoni F. Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J Infect Dis. 1994 Jun;169(6):1325–1331. doi: 10.1093/infdis/169.6.1325. [DOI] [PubMed] [Google Scholar]
  45. Redmond H. P., Shou J., Gallagher H. J., Kelly C. J., Daly J. M. Macrophage-dependent candidacidal mechanisms in the murine system. Comparison of murine Kupffer cell and peritoneal macrophage candidacidal mechanisms. J Immunol. 1993 Apr 15;150(8 Pt 1):3427–3433. [PubMed] [Google Scholar]
  46. Riipi L., Carlson E. Tumor necrosis factor (TNF) is induced in mice by Candida albicans: role of TNF in fibrinogen increase. Infect Immun. 1990 Sep;58(9):2750–2754. doi: 10.1128/iai.58.9.2750-2754.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Romani L., Mencacci A., Grohmann U., Mocci S., Mosci P., Puccetti P., Bistoni F. Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. J Exp Med. 1992 Jul 1;176(1):19–25. doi: 10.1084/jem.176.1.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Romani L., Puccetti P., Mencacci A., Cenci E., Spaccapelo R., Tonnetti L., Grohmann U., Bistoni F. Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J Immunol. 1994 Apr 1;152(7):3514–3521. [PubMed] [Google Scholar]
  49. Smith J. G., Magee D. M., Williams D. M., Graybill J. R. Tumor necrosis factor-alpha plays a role in host defense against Histoplasma capsulatum. J Infect Dis. 1990 Dec;162(6):1349–1353. doi: 10.1093/infdis/162.6.1349. [DOI] [PubMed] [Google Scholar]
  50. Steinshamn S., Waage A. Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice. Infect Immun. 1992 Oct;60(10):4003–4008. doi: 10.1128/iai.60.10.4003-4008.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  52. Tracey K. J., Vlassara H., Cerami A. Cachectin/tumour necrosis factor. Lancet. 1989 May 20;1(8647):1122–1126. doi: 10.1016/s0140-6736(89)92394-5. [DOI] [PubMed] [Google Scholar]
  53. Valone F. H., Epstein L. B. Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-beta, tumor necrosis factor, or IFN-gamma. J Immunol. 1988 Dec 1;141(11):3945–3950. [PubMed] [Google Scholar]
  54. Voelkel N. F., Worthen S., Reeves J. T., Henson P. M., Murphy R. C. Nonimmunological production of leukotrienes induced by platelet-activating factor. Science. 1982 Oct 15;218(4569):286–289. doi: 10.1126/science.7123233. [DOI] [PubMed] [Google Scholar]
  55. Zacharchuk C. M., Drysdale B. E., Mayer M. M., Shin H. S. Macrophage-mediated cytotoxicity: role of a soluble macrophage cytotoxic factor similar to lymphotoxin and tumor necrosis factor. Proc Natl Acad Sci U S A. 1983 Oct;80(20):6341–6345. doi: 10.1073/pnas.80.20.6341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. van 't Wout J. W., Linde I., Leijh P. C., van Furth R. Contribution of granulocytes and monocytes to resistance against experimental disseminated Candida albicans infection. Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):736–741. doi: 10.1007/BF01975039. [DOI] [PubMed] [Google Scholar]
  57. von Asmuth E. J., Maessen J. G., van der Linden C. J., Buurman W. A. Tumour necrosis factor alpha (TNF-alpha) and interleukin 6 in a zymosan-induced shock model. Scand J Immunol. 1990 Oct;32(4):313–319. doi: 10.1111/j.1365-3083.1990.tb02925.x. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES